The Türkiye Heart Failure Registry

NCT ID: NCT06707220

Last Updated: 2025-03-03

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 5000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-01-08
• Study Completion Date: 2027-12-31

Brief Summary

A comprehensive understanding of the socio-demographic, clinical, and biological characteristics of patients with heart failure is essential to develop novel strategies for improving outcomes. The identification of the barriers to guideline-directed medical therapy implementation in a real-world setting is critical to decreasing the risk of heart failure hospitalization and mortality. A comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient, physician, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy. It should be noted that the number of heart failure registries that enroll patients with de novo heart failure, chronic heart failure (outpatients), and worsening of heart failure (hospitalized or treated in the emergency department), with all three relevant ejection fraction categories (heart failure with reduced ejection fraction, heart failure with mildly-reduced ejection fraction, and heart failure with preserved ejection fraction), is limited. Furthermore, only a few registries assess detailed aspects of guideline adherence, treatment decisions, and both in-hospital and long-term outcomes. Therefore, the Türkiye Heart Failure (TURK-HF) registry has been designed to address this gap in knowledge about the identification, management, and long-term prognosis of patients with heart failure in a real-world setting.

Conditions

Heart Failure

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Heart failure medication

Treated with optimal guideline-directed medical therapy

Intervention Type: OTHER

Eligibility Criteria

Exclusion Criteria

-

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baskent University

OTHER

Sponsor Role: lead

Responsible Party

Umut Kocabas

Medical Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Baskent University

Ankara, Ankara, Turkey (Türkiye)

Site Status: RECRUITING

Countries

Turkey (Türkiye)

Central Contacts

Umut Kocabaş

Role: CONTACT

umutkocabas@hotmail.com

+905079974999

Facility Contacts

Umut Kocabaş, M.D.

Role: primary

umutkocabas@hotmail.com

+905079974999

References

Kocabas U, Ergin I, Yavuz V, Altin C, Kaplan M, Yilmaz Oztekin GM, Dogdus M, Murat S, Murat B, Kivrak T, Karabulut D, Kaya E, Ozdemir IH, Yildiz C, Salkin FO, Ozcalik E, Polatkan SG, Cakan F, Sen T, Karabulut U, Cakal S, Oflar E, Sinan UY, Yenercag M, Turk UO. Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study. ESC Heart Fail. 2025 Feb;12(1):434-446. doi: 10.1002/ehf2.15049. Epub 2024 Sep 28.

Reference Type: BACKGROUND

PMID: 39340234 (View on PubMed)

Kocabas U, Ergin I, Kivrak T, Yilmaz Oztekin GM, Tanik VO, Ozdemir I, Avci Demir F, Dogdus M, Sen T, Altinsoy M, Ustundag S, Urgun OD, Sinan UY, Uygur B, Yeni M, Ozcalik E. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2023 Dec;10(6):3677-3689. doi: 10.1002/ehf2.14559. Epub 2023 Oct 7.

Reference Type: BACKGROUND

PMID: 37804042 (View on PubMed)

Kocabas U, Kivrak T, Yilmaz Oztekin GM, Tanik VO, Ozdemir IH, Kaya E, Yuce EI, Avci Demir F, Dogdus M, Altinsoy M, Ustundag S, Ozyurtlu F, Karagoz U, Karakus A, Urgun OD, Sinan UY, Mutlu I, Sen T, Astarcioglu MA, Kinik M, Tok OO, Uygur B, Yeni M, Alan B, Dalgic O, Sariturk C, Altay H, Pehlivanoglu S. Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with reduced ejection fraction: The ATA study. Anatol J Cardiol. 2020 Jul;24(1):32-40. doi: 10.14744/AnatolJCardiol.2020.91771.

Reference Type: BACKGROUND

PMID: 32628147 (View on PubMed)

Other Identifiers

KA23/429

Identifier Type: -

Identifier Source: org_study_id